cyclophosphamide + prednisone + doxorubicin + cisplatin + carmustine

This is a combination chemotherapy regimen containing five drugs: **cyclophosphamide** (an alkylating agent), **prednisone** (a corticosteroid), **doxorubicin** (an anthracycline antineoplastic), **cisplatin** (a platinum-based chemotherapy), and **carmustine** (an alkylating nitrosourea). These agents together provide broad-spectrum cytotoxic effects through multiple mechanisms: DNA alkylation (cyclophosphamide, carmustine, cisplatin), immunosuppression and anti-inflammatory action (prednisone), and DNA intercalation plus topoisomerase II inhibition (doxorubicin). This regimen is designed for intensive chemotherapy, most notably for refractory or relapsed lymphomas (such as Hodgkin's or Non-Hodgkin lymphoma) and may be used as conditioning for stem cell transplantation or as salvage therapy in resistant disease[2][1]. It is not a widely standardized regimen; similar combinations are referenced in clinical studies as modifications or alternatives to more established regimens, sometimes with etoposide or substitutions in the regimen[2][1][4][3][5].